Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design

NCT04185857 is registered in ClinicalTrials.gov with University Hospital Padova as lead sponsor.

NCT NCT04185857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04185857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design
Lead sponsor
University Hospital Padova
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
October 25, 2019
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary aldosteronism due to aldosterone producing adenoma